e-learning
resources
Munich 2014
Monday, 08.09.2014
Pathogenetic mechanisms in pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LSC 2014 abstract - M1/ M2 subpopulations of macrophages in patients with sarcoidosis- influence of smoking status
I. Osinska, D. Wolosz, T. Urbankowski, J. Domagala-Kulawik (Warsaw, Poland)
Source:
International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Session:
Pathogenetic mechanisms in pulmonary fibrosis
Session type:
Oral Presentation
Number:
1733
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Osinska, D. Wolosz, T. Urbankowski, J. Domagala-Kulawik (Warsaw, Poland). LSC 2014 abstract - M1/ M2 subpopulations of macrophages in patients with sarcoidosis- influence of smoking status. Eur Respir J 2014; 44: Suppl. 58, 1733
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Related content which might interest you:
Impact of smoking habit on lung function in a large cohort sarcoidosis patients.
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Assessing sarcoidosis activity: Is serum chitotriosidase a reliable marker? Study of 430 patients and 264 healthy controls
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Does the
BTNL2
genotype influence the course of disease in Danish sarcoidosis patients?
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used
Source: International Congress 2017 – Rare diseases
Year: 2017
Mindfulness-based stress reduction in patients with interstitial lung disease: A pilot study
Source: International Congress 2014 – ILDs 3
Year: 2014
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014
Fibrosis in emphysema: Radiologically occult but histologically prevalent process proportionate to smoking burden
Source: International Congress 2014 – ILDs 6
Year: 2014
Mutation alone does not predict the clinical course of surfactant protein C deficiency in children
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
LSC 2014 abstract - Evaluation of paraoxonase1 activity and its relationship to the severity of lung impairment in COPD
Source: International Congress 2014 – Translational studies in COPD
Year: 2014
Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014
Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 5
Year: 2014
Serum levels of sestrin 2 in patients with sarcoidosis
Source: International Congress 2014 – ILDs 6
Year: 2014
Live patient and partner survey on pulmonary fibrosis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Asbestos-related disorders (ARDs): Influence of pleural plaques and pulmonary fibrosis due to asbestos exposure on lung function decline (LFD)
Source: International Congress 2014 – ILDs 5
Year: 2014
Beneficial effect of azithromycin in children with diffuse parenchymal lung disease
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Lung asbestos content in patients with lung cancer in different Spanish regions. The AMCANES study
Source: International Congress 2016 – Human responses to exposure, including physiological and biomarker outcomes
Year: 2016
Residential radon and lung cancer histological types in never smokers
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Mucus production, lung inflammation and functional decay in IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia
Source: International Congress 2014 – ILDs 3
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept